Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

8.800 +0.420 (+5.01%)
Streaming Delayed Price Updated: 2:11 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89Bio Inc

< Previous 1 2 3 4 5 6 7 8 Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
Analyst Ratings for 89bio
Via Benzinga
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
89bio to Participate in the Leerink Partners Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following... 
Via Benzinga
Topics Stocks
Exposures US Equities
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in  
Via Benzinga
Exposures Product Safety
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
From 89bio, Inc.
Via GlobeNewswire
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with  
Via Benzinga
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.